Aclaris Therapeutics, Inc. (ACRS) SEC Filing 10-K Annual report for the fiscal year ending Sunday, December 31, 2017

Exhibit 99.1

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Clinical and Commercial Developments

Wayne, PA – March 12, 2018 (GLOBE NEWSWIRE) –

“2017 was a defining year in Aclaris’ history, with the FDA approval of ESKATA™ (hydrogen peroxide) Topical Solution, 40% (w/w),  the first and only FDA-approved topical, non-invasive treatment of raised seborrheic keratosis (SK). We  have generated a high level of excitement around ESKATA in the dermatology community, and look forward to our official launch in the second quarter of 2018,” said Dr. Neal Walker, President and Chief Executive Officer of Aclaris. “In January 2018, we announced positive topline results from two Phase 2 clinical trials (WART-202 and WART-203) of A-101 45% Topical Solution (A-101 45%) for the treatment of common warts (verruca vulgaris). We also advanced our topical Janus kinase (JAK) inhibitor programs in alopecia, with results from multiple Phase 2 trials expected later this year. As our early-stage pipeline compounds advance towards the clinic, we continue to progress towards our goal of becoming a vertically integrated, commercial-stage biopharmaceutical company with a robust clinical-stage pipeline and drug discovery engine.”

Clinical Pipeline Update